Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd decreased its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 87.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 38,241 shares of the biopharmaceutical company's stock after selling 270,739 shares during the period. WINTON GROUP Ltd owned about 0.08% of Puma Biotechnology worth $117,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Puma Biotechnology by 169.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 30,499 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Puma Biotechnology by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 11,252 shares in the last quarter. FMR LLC boosted its stake in shares of Puma Biotechnology by 27.1% during the third quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company's stock valued at $302,000 after acquiring an additional 25,183 shares during the last quarter. Barclays PLC increased its position in Puma Biotechnology by 146.5% during the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company's stock worth $199,000 after purchasing an additional 46,370 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new position in Puma Biotechnology in the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 61.29% of the company's stock.

Puma Biotechnology Trading Down 0.7 %

Puma Biotechnology stock traded down $0.02 during trading on Friday, hitting $2.90. The company's stock had a trading volume of 367,741 shares, compared to its average volume of 440,822. The stock's fifty day moving average is $3.10 and its 200 day moving average is $2.99. Puma Biotechnology, Inc. has a 1-year low of $2.23 and a 1-year high of $6.06. The stock has a market capitalization of $143.87 million, a price-to-earnings ratio of 6.04 and a beta of 1.33. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. As a group, equities research analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PBYI shares. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 8th. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.